Delmar Pharmaceuticals Inc., of Vancouver, British Columbia, presented preclinical data at the American Association for Cancer Research Advances in Ovarian Cancer Research: Exploiting Vulnerabilities Conference in Orlando, Fla., demonstrating the potential of its lead product candidate, VAL-083, (dianhydrogalactitol) as a treatment for ovarian cancer.